Jove
Visualize
Contact Us

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

400
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
400
Vaccinations01:51

Vaccinations

44.7K
Overview
44.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASCCP President 's Message.

Journal of lower genital tract disease·2026
Same author

Why Gynecologists Must Become Anal Cancer-Prevention Specialists.

Obstetrics and gynecology·2026
Same author

Addressing Cervical Cancer Screening Disparities: At-Home Self-Collection Among LGBQ+ Populations.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Are gynecologists prepared to offer anal cancer prevention services?: a qualitative study of barriers to implementation in the United States.

Preventive medicine reports·2026
Same author

Experiences of OBGYN Administrative Chief Residents.

Journal of surgical education·2026
Same author

Virtual patients, real learning: extended reality simulation for clinical menopause education.

Menopause (New York, N.Y.)·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 17, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.5K

Human Papillomavirus Vaccines.

Christine Conageski1

  • 1Department of OBGYN, University of Colorado School of Medicine, Aurora, Colorado.

Clinical Obstetrics and Gynecology
|August 31, 2023
PubMed
Summary
This summary is machine-generated.

Human papillomavirus (HPV) vaccines are highly effective in preventing HPV transmission and related cancers. Continued research into new vaccines and strategies to combat hesitancy are crucial for widespread HPV prevention.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.0K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.5K

Related Experiment Videos

Last Updated: Jul 17, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.5K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.0K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.5K

Area of Science:

  • Immunology
  • Oncology
  • Public Health

Background:

  • Human papillomavirus (HPV) vaccines, available since 2006, are crucial for preventing HPV transmission and associated lower genital tract neoplasias.
  • Clinical studies confirm the efficacy and robust safety profiles of HPV vaccines in both males and females.
  • While several HPV vaccines exist globally, only one is currently approved in the United States.

Purpose of the Study:

  • To review the efficacy, safety, and current recommendations for HPV vaccination.
  • To explore emerging research in novel DNA vaccines and delivery systems for HPV.
  • To address challenges in HPV vaccination rates, including hesitancy and disinformation.

Main Methods:

  • Review of prelicensure and postlicensure studies on HPV vaccine safety and efficacy.
  • Analysis of current vaccination guidelines and recommendations for expanded populations.
  • Examination of recent research on novel HPV vaccine technologies and interventions.

Main Results:

  • HPV vaccines demonstrate high efficacy in preventing HPV infection and related precancerous lesions.
  • Established HPV vaccines have proven safety profiles.
  • Newer DNA vaccine technologies show promise in eliminating existing HPV infections.

Conclusions:

  • HPV vaccination is recommended for individuals aged 9-26, with expanded recommendations based on shared decision-making.
  • Despite proven benefits, vaccination hesitancy and misinformation pose significant barriers to HPV elimination.
  • Targeted interventions are necessary to increase HPV vaccination rates and achieve cancer prevention goals.